These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The molecular basis of antisickling agents. Franklin IM; Huehns ER Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123 [No Abstract] [Full Text] [Related]
23. New antisickling agents. Labie D Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483 [TBL] [Abstract][Full Text] [Related]
24. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde. Manning JM; Acharya AS Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764 [TBL] [Abstract][Full Text] [Related]
25. Understanding antisickling agents and the sickling process. Godwin M; Baysinger M Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864 [No Abstract] [Full Text] [Related]
26. New treatments for sickle cell disease. Med Lett Drugs Ther; 1973 Feb; 15(4):17-9. PubMed ID: 4695516 [No Abstract] [Full Text] [Related]
27. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia. Vicari P; Barretto de Mello A; Figueiredo MS Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590 [TBL] [Abstract][Full Text] [Related]
28. Sickle cell anemia: targeting the role of fetal hemoglobin in therapy. Coleman E; Inusa B Clin Pediatr (Phila); 2007 Jun; 46(5):386-91. PubMed ID: 17556734 [TBL] [Abstract][Full Text] [Related]
29. The treatment of sickle-cell disease. Lancet; 1972 Mar; 1(7752):671-2. PubMed ID: 4125168 [No Abstract] [Full Text] [Related]
31. Hydroxyurea and new agents for the treatment of sickle cell disease. Rodgers GP Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257 [No Abstract] [Full Text] [Related]
32. Sickle cell patients find a brand New World. Noonan SS N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727 [TBL] [Abstract][Full Text] [Related]
36. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Charache S Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197 [TBL] [Abstract][Full Text] [Related]
37. Future directions in sickle cell disease. Anand A West J Med; 1993 May; 158(5):536-7. PubMed ID: 8342283 [No Abstract] [Full Text] [Related]
38. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts). Dean J; Schechter AN N Engl J Med; 1978 Oct; 299(16):863-70. PubMed ID: 692579 [No Abstract] [Full Text] [Related]
39. Sickle cell disease: advances in the 1970s and challenge in the 1980s. Bunn HF Am J Pediatr Hematol Oncol; 1982; 4(2):166-71. PubMed ID: 6180652 [TBL] [Abstract][Full Text] [Related]
40. Current status of methyl acetimidate as an extracorporeal antisickling agent. Chao TL; Berenfeld MR; Gabuzda TG Am J Pediatr Hematol Oncol; 1984; 6(1):55-8. PubMed ID: 6711765 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]